Resverlogix Corp. announced last week that it's spinning out its epigenetics platform into RVX Therapeutics Inc., leaving its ApoA-I stimulating drug candidate, RVX-208, with the parent company. Read More
WASHINGTON – At the annual meeting of the American Association for Cancer Research (AACR) last week, researchers were touting the potential of immunotherapies at the same time as they were trying to figure out how to meet their unique regulatory and developmental challenges. Read More
Like the number of biotech initial public offerings (IPOs) that are completed annually, another closely tracked statistic is the transactional value of the industry's mergers and acquisitions (M&As) and partnering deal flow. The number of deals concluded each year provides a measure of the vibrancy of the sector, its business strategies and technology aspirations. Read More
